JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - MINERVA NEUROSCIENCES INC
Financial Performance:
- No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed as the company is in clinical development and pre-commercialization.
- Raised $200 million in financing in October of the prior year to support ongoing operations and future commercialization efforts.
- Explicitly noted that the recent capital raise is insufficient to fully fund the commercialization infrastructure required post-approval.
Guidance and Future Outlook:
- Phase 3a (Confirmatory) Readout: Expected in the second half of 2027 for Part A (12-week efficacy data).
- Phase 3b (Safety/Relapse) Readout: Expected in the second half of 2028 for Part B (one-year safety and relapse comparison).
- Long-term Goal: Establish Roliparidone as a monotherapy for stable schizophrenia patients with negative symptoms, shifting away from continuous antipsychotic use.
- Commercialization: Actively preparing commercialization strategies, including patient/caregiver education and prescriber training, ahead of the 2027 data readout.
Business Segments and Product Lines:
- Product: Roliparidone, a novel therapeutic targeting negative symptoms in schizophrenia.
- Mechanism: Utilizes 5-HT2A serotonergic activity rather than dopaminergic D2 blockade to avoid worsening negative symptoms.
- Study Design: Confirmatory trial includes Part A (efficacy vs. placebo) and Part B (safety/relapse vs. antipsychotics).
- Patient Selection: Focusing on a specific subset of ~900,000 US patients with stable positive symptoms and impairing negative symptoms.
- Patent Estate: Holds a composition of matter patent expiring in 2038 (plus pediatric extensions); includes a complex formulation/process patent (not standard formulation) and other families pending inclusion in the Orange Book.
Market and Competitive Landscape:
- Market Size: Addresses ~900,000 target patients in the US out of a total schizophrenia population of ~3.2 million.
- Competitive Gap: Current antipsychotics treat positive symptoms but often worsen negative symptoms; no existing approved therapy specifically targets negative symptoms in stable patients.
- Clinical Differentiation: Roliparidone demonstrates a low relapse rate (10-15% over one year) compared to the 27-30% relapse rate typically seen with antipsychotics in meta-analyses.
- Regulatory Path: FDA has aligned with the company's approach following a public meeting, validating the need for stable patient populations and long-term placebo-controlled studies.
Risks and Challenges:
- Screening Complexity: High screen failure rates due to strict criteria requiring 6-month stability and specific negative symptom scores (e.g., PANSS-MARTAR >20).
- Placebo Control: Managing high placebo responses and "nursing effects" in patients with negative symptoms (amotivation, lack of pleasure); mitigated by minimizing patient-site contact to caregiver-only interactions.
- Regulatory Uncertainty: While FDA dialogue is constructive, the final determination on the black box warning and labeling remains with the agency.
- Commercial Execution: Significant need for capital to build marketing, distribution, and educational infrastructure post-approval.
Management Commentary and Tone:
- Tone: Highly confident and constructive; management emphasizes a "paradigm shift" in treating schizophrenia.
- Expertise: CEO Remy Luthringer speaks from clinical background, validating the biological rationale for avoiding dopamine blockade.
- Data Integrity: Highlights rigorous data quality, noting that strict inclusion criteria (e.g., rejecting patients with scores of 19 vs. 20) indicate high site performance and low variability.
- Strategic Focus: Emphasizes accumulating evidence of functional improvement (PSP scores) rather than just symptom scores.
Analyst Questions and Answers:
- Q: How does Roliparidone compare to antipsychotics regarding negative symptoms?
- A: Antipsychotics do not help negative symptoms and often worsen them (secondary negative symptoms); Roliparidone aims to treat these specifically.
- Q: How did the company control for placebo in Phase 3?
- A: Used a single high dose (64mg) to maximize the treatment delta; implemented patient selection committees; reduced site variability via detailed scorer retraining; minimized "nursing effect" by limiting direct patient interaction.
- Q: What are the relapse rates observed?
- A: Roliparidone showed 10-15% relapse over one year vs. 27-30% for antipsychotics in historical data; Part B aims to show similar relapse rates between the two treatments to support monotherapy.
- Q: Why is the primary endpoint set at 12 weeks if the study is longer?
- A: Phase 3a is powered to show a statistically significant difference (1-2 point delta) on the PANSS-MARTAR at week 12; Phase 3b is purely for safety/descriptive relapse data.
- Q: How does Roliparidone compare to antipsychotics regarding negative symptoms?
Other Key Points:
- Drug Name: The transcript mentions the drug as "Rhooperidone" and "Roliparidone"; standard pharmaceutical spelling is likely "Roliperidone" (clarification needed based on external knowledge, but transcript uses these variations).
- Safety Profile: No black box warning anticipated for Roliparidone as it does not block post-synaptic D2 receptors, which is a primary driver of mortality in traditional antipsychotics.
- Study Specifics: Dropout rates in previous studies were ~30%, but over half were due to personal/family reasons rather than drug toxicity.
- Market Strategy: Management is preparing to educate the market on the concept of "treatment-free" maintenance for stable patients, contrasting with current standard of care.
- Company
- MINERVA NEUROSCIENCES INC
- Keywords
- MINERVA NEUROSCIENCES INC